Luke H Stockwin
Leeds University, UK - PhD in cancer Immunobiology.
Oxford Glycosciences, UK - Proteomic characterization of cancer cell surface markers - with development of humanized therapeutic monoclonal antibodies.
FNLCR Developmental Therapeutic Program [DTP] mechanism group - Proteomic Identification of small-molecule response biomarkers, mechanistic studies of small molecules, transcriptomics of xenograft models and rare tumors.
FNLCR Patient-derived model [PDM] initiative - development of a platform for the rapid derivation and molecular characterization of cancer cell lines and CAFs from tumor biopsies and patient-derived xenografts.